Cargando…

STEAP1 regulation and its influence modulating the response of LNCaP prostate cancer cells to bicalutamide, enzalutamide and apalutamide

Anti-androgen drugs are the standard pharmacological therapies for treatment of non-metastatic prostate cancer (PCa). However, the response of PCa cells may depend on the anti-androgen used and often patients become resistant to treatment. Thus, studying how the anti-androgen drugs affect oncogenes...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rocha, Sandra M., Nascimento, Daniel, Cardoso, Ana Margarida, Passarinha, Luís, Socorro, Sílvia, Maia, Cláudio J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9879076/ https://www.ncbi.nlm.nih.gov/pubmed/36660947 http://dx.doi.org/10.3892/mmr.2023.12939

Ejemplares similares

STEAP1 Knockdown Decreases the Sensitivity of Prostate Cancer Cells to Paclitaxel, Docetaxel and Cabazitaxel
por: Rocha, Sandra M., et al.
Publicado: (2023)

Enhanced Antitumor Efficacy of Radium-223 and Enzalutamide in the Intratibial LNCaP Prostate Cancer Model
por: Suominen, Mari I., et al.
Publicado: (2023)

Salmon Protein Hydrolysate Potentiates the Growth Inhibitory Effect of Bicalutamide on Human Prostate Cancer Cell Lines LNCaP and PC3 by Modulating Iron Homeostasis
por: Bjerknes, Christian, et al.
Publicado: (2022)

ADAMTS1 alters blood vessel morphology and TSP1 levels in LNCaP and LNCaP-19 prostate tumors
por: Gustavsson, Heléne, et al.
Publicado: (2010)

Promoter Demethylation Upregulates STEAP1 Gene Expression in Human Prostate Cancer: In Vitro and In Silico Analysis
por: Rocha, Sandra M., et al.
Publicado: (2021)

STEAP1 expression in prostate cancer and its regulation by androgens
por: Gomes, Inês, et al.
Publicado: (2010)

Calcitriol and TO-901317 Interact in Human Prostate Cancer LNCaP Cells
por: Wang, Jing-Huan, et al.
Publicado: (2008)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Role of Testosterone Levels on the Combinatorial Effect of Boswellia serrata Extract and Enzalutamide on Androgen Dependent LNCaP Cells and in Patient Derived Cells
por: Pillai, Prathesha, et al.
Publicado: (2021)

Expression of STEAP1 and STEAP1B in prostate cell lines, and the putative regulation of STEAP1 by post-transcriptional and post-translational mechanisms
por: Gomes, Inês M., et al.
Publicado: (2014)

Androgen upregulates the palmitoylation of eIF3L in human prostate LNCaP cells
por: Cui, Luwei, et al.
Publicado: (2019)

Corrigendum to Role of Testosterone Levels on the Combinatorial Effect of Boswellia serrata Extract and Enzalutamide on Androgen Dependent LNCaP Cells and in Patient Derived Cells
Publicado: (2021)

Enhanced Stability of Detergent-Free Human Native STEAP1 Protein from Neoplastic Prostate Cancer Cells upon an Innovative Isolation Procedure
por: Barroca-Ferreira, Jorge, et al.
Publicado: (2021)

Apogossypolone inhibits the proliferation of LNCaP cells in vitro and in vivo
por: ZHANG, XIANQING, et al.
Publicado: (2014)

Apogossypolone inhibits the proliferation of LNCaP cells in vitro and in vivo
por: Zhang, Xianqing, et al.
Publicado: (2018)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Differentiation enhances aminolevulinic acid-dependent photodynamic treatment of LNCaP prostate cancer cells
por: Ortel, B, et al.
Publicado: (2002)

Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP.
por: Wolf, D. A., et al.
Publicado: (1991)

LNCaP Atlas: Gene expression associated with in vivo progression to castration-recurrent prostate cancer
por: Romanuik, Tammy L, et al.
Publicado: (2010)

Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment
por: Sieh, Shirly, et al.
Publicado: (2012)

EphA2 enhances the proliferation and invasion ability of LNCaP prostate cancer cells
por: CHEN, PEIJIE, et al.
Publicado: (2014)

MiR‐145 affected the circular RNA expression in prostate cancer LNCaP cells
por: He, Jin‐Hua, et al.
Publicado: (2018)

Effect of CD133 overexpression on bone metastasis in prostate cancer cell line LNCaP
por: Sohn, Hong Moon, et al.
Publicado: (2019)

Effects of 14 frequently used drugs on prostate-specific antigen expression in prostate cancer LNCaP cells
por: IGUCHI, KAZUHIRO, et al.
Publicado: (2014)

Alteration of Androgen Receptor Protein Stability by Triptolide in LNCaP Cells
por: Li, Wei, et al.
Publicado: (2018)

URG11 promotes proliferation and induced apoptosis of LNCaP cells
por: Sun, Chenmin, et al.
Publicado: (2019)

Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model
por: Rothermund, Christy A, et al.
Publicado: (2005)

Interleukin 1beta mediates the modulatory effects of monocytes on LNCaP human prostate cancer cells.
por: Culig, Z., et al.
Publicado: (1998)

Analysis of the prostate cancer cell line LNCaP transcriptome using a sequencing-by-synthesis approach
por: Bainbridge, Matthew N, et al.
Publicado: (2006)

Selenium enrichment of broccoli sprout extract increases chemosensitivity and apoptosis of LNCaP prostate cancer cells
por: Abdulah, Rizky, et al.
Publicado: (2009)

Correction: Phenotypic Characterization of Prostate Cancer LNCaP Cells Cultured within a Bioengineered Microenvironment
por: Sieh, Shirly, et al.
Publicado: (2013)

Role of Androgen Receptor in Progression of LNCaP Prostate Cancer Cells from G(1) to S Phase
por: Murthy, Shalini, et al.
Publicado: (2013)

Inhibition of IL-6 expression in LNCaP prostate cancer cells by a combination of atorvastatin and celecoxib
por: WANG, HUAQIAN, et al.
Publicado: (2014)

Role of EZH2 in the Growth of Prostate Cancer Stem Cells Isolated from LNCaP Cells
por: Li, Kuiqing, et al.
Publicado: (2013)

Synergistic Effects of NDRG2 Overexpression and Radiotherapy on Cell Death of Human Prostate LNCaP Cells
por: Alizadeh Zarei, M., et al.
Publicado: (2017)

MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells
por: Nam, Robert K., et al.
Publicado: (2018)

Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines
por: Seim, Inge, et al.
Publicado: (2017)

The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells
por: Morell, C, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mne2mlquk74hjhudi20vvcu0la